JP2011527709A - 眼瞼炎の治療方法 - Google Patents
眼瞼炎の治療方法 Download PDFInfo
- Publication number
- JP2011527709A JP2011527709A JP2011517670A JP2011517670A JP2011527709A JP 2011527709 A JP2011527709 A JP 2011527709A JP 2011517670 A JP2011517670 A JP 2011517670A JP 2011517670 A JP2011517670 A JP 2011517670A JP 2011527709 A JP2011527709 A JP 2011527709A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- blepharitis
- azithromycin
- eye
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000010217 blepharitis Diseases 0.000 title claims abstract description 120
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims abstract description 114
- 229960004099 azithromycin Drugs 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 68
- 230000001684 chronic effect Effects 0.000 claims abstract description 39
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 37
- 206010013774 Dry eye Diseases 0.000 claims abstract description 28
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 claims abstract description 18
- 230000002458 infectious effect Effects 0.000 claims abstract description 13
- 206010010804 Contact lens intolerance Diseases 0.000 claims abstract description 12
- 230000000699 topical effect Effects 0.000 claims description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 10
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 5
- 229950005134 polycarbophil Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000011282 treatment Methods 0.000 description 55
- 210000000744 eyelid Anatomy 0.000 description 50
- 208000024891 symptom Diseases 0.000 description 46
- 210000004175 meibomian gland Anatomy 0.000 description 36
- 229940006387 azasite Drugs 0.000 description 26
- 208000002193 Pain Diseases 0.000 description 23
- 239000003814 drug Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 239000000203 mixture Substances 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 16
- 230000028327 secretion Effects 0.000 description 15
- 206010015150 Erythema Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 239000006196 drop Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 229940006385 azithromycin ophthalmic solution Drugs 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000000607 artificial tear Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 206010015958 Eye pain Diseases 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 201000003265 lymphadenitis Diseases 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 208000012868 Overgrowth Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- ZZUUMCMLIPRDPI-UHFFFAOYSA-N 2-hydroxypropanoic acid;sodium Chemical compound [Na].CC(O)C(O)=O ZZUUMCMLIPRDPI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- -1 dextran Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000008397 ocular pathology Effects 0.000 description 1
- 239000008217 ophthalmic excipient Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7977208P | 2008-07-10 | 2008-07-10 | |
| US61/079,772 | 2008-07-10 | ||
| PCT/US2009/050311 WO2010006306A1 (en) | 2008-07-10 | 2009-07-10 | Method of treating blepharitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014190105A Division JP2014240433A (ja) | 2008-07-10 | 2014-09-18 | 眼瞼炎の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527709A true JP2011527709A (ja) | 2011-11-04 |
| JP2011527709A5 JP2011527709A5 (enExample) | 2012-07-12 |
Family
ID=41507457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517670A Withdrawn JP2011527709A (ja) | 2008-07-10 | 2009-07-10 | 眼瞼炎の治療方法 |
| JP2014190105A Ceased JP2014240433A (ja) | 2008-07-10 | 2014-09-18 | 眼瞼炎の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014190105A Ceased JP2014240433A (ja) | 2008-07-10 | 2014-09-18 | 眼瞼炎の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8349806B2 (enExample) |
| EP (1) | EP2313103B1 (enExample) |
| JP (2) | JP2011527709A (enExample) |
| AU (1) | AU2009268372B2 (enExample) |
| CA (1) | CA2730120A1 (enExample) |
| MX (1) | MX2011000247A (enExample) |
| WO (1) | WO2010006306A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014023526A (ja) * | 2012-06-19 | 2014-02-06 | Santen Pharmaceut Co Ltd | ヘアレス動物の眼瞼状態の変化方法 |
| JPWO2017110874A1 (ja) * | 2015-12-22 | 2018-11-15 | 日油株式会社 | 涙液油層安定化剤およびこれを含有する点眼剤 |
| WO2021261576A1 (ja) * | 2020-06-26 | 2021-12-30 | 参天製薬株式会社 | 脂質分泌促進剤 |
| JP2023550632A (ja) * | 2020-11-23 | 2023-12-04 | サイト サイエンシーズ， インコーポレイテッド | 眼の症状を処置するための製剤および方法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925087B2 (en) | 2000-09-15 | 2018-03-27 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
| US10105259B2 (en) | 2000-09-15 | 2018-10-23 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
| ATE460146T1 (de) | 2000-09-15 | 2010-03-15 | Bruder Healthcare Co | Wund- und behandlungskompresse und verband |
| US8349806B2 (en) | 2008-07-10 | 2013-01-08 | Inspire Pharmaceuticals, Inc. | Method of treating blepharitis |
| US20100190734A1 (en) * | 2009-01-23 | 2010-07-29 | Romulus Kimbro Brazzell | Method of treating dry eye disease with azithromycin |
| US20130281390A1 (en) * | 2010-12-29 | 2013-10-24 | Kurt E. Brubaker | Method for treating dry eye |
| WO2012092378A1 (en) * | 2010-12-29 | 2012-07-05 | Inspire Pharmaceuticals, Inc. | Method for treating blepharitis |
| JP2014518275A (ja) * | 2011-06-29 | 2014-07-28 | インサイト・ビジョン・インコーポレイテッド | 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法 |
| WO2014143139A1 (en) | 2013-03-15 | 2014-09-18 | Bruder Healthcare Company | Wound and therapy compress and dressing |
| CN104045674B (zh) * | 2014-05-21 | 2017-01-04 | 丽珠医药集团股份有限公司 | 一种阿奇霉素的制备方法 |
| CN105106109A (zh) * | 2015-09-11 | 2015-12-02 | 江苏锦宇环境工程有限公司 | 一种阿奇霉素缓释滴眼剂的制备方法 |
| US12029681B2 (en) | 2016-03-01 | 2024-07-09 | The Hilsinger Company Parent, Llc | Therapeutic eye mask system |
| US12011388B2 (en) | 2016-03-01 | 2024-06-18 | The Hilsinger Company Parent, Llc | Therapeutic thermal compress with phase-change material |
| US12156831B2 (en) | 2016-03-01 | 2024-12-03 | The Hilsinger Company Parent, Llc | Therapeutic eye compress system |
| US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
| USD844795S1 (en) | 2016-11-30 | 2019-04-02 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| USD871598S1 (en) | 2016-11-30 | 2019-12-31 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| CN109381707B (zh) * | 2017-08-03 | 2022-02-15 | 沈阳药科大学 | 一种阿奇霉素离子对脂质体滴眼液及其制备方法 |
| US20240050446A1 (en) * | 2021-02-25 | 2024-02-15 | Sun Pharmaceutical Industries Limited | Dexamethasone for treatment of blepharitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001089378A (ja) * | 1999-08-09 | 2001-04-03 | Sifi Soc Industria Farmaceutica It Spa | 眼科用水性薬剤の製造方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861411B1 (en) | 1997-12-02 | 2005-03-01 | Pfizer, Inc. | Method of treating eye infections with azithromycin |
| ATE319456T1 (de) | 1998-05-08 | 2006-03-15 | Univ Miami | Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen |
| US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| AR031135A1 (es) | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| HRP20010301A2 (en) * | 2001-04-27 | 2001-12-31 | Pliva D D | New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases |
| WO2004091436A2 (en) | 2003-04-15 | 2004-10-28 | The Regents Of The University Of California | Methods and compositions for treating ocular disease |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| US20050137205A1 (en) * | 2003-12-22 | 2005-06-23 | Van Breen Eduard T. | Formulation for treating periocular disease |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US8372814B2 (en) | 2004-06-07 | 2013-02-12 | Ista Pharmaceuticals, Inc. | Ophthalmic formulations and uses thereof |
| US8349352B2 (en) | 2005-02-04 | 2013-01-08 | Auburn University | Therapeutic contact lenses with anti-fungal delivery |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| US7247623B2 (en) | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
| US20070105788A1 (en) * | 2005-11-09 | 2007-05-10 | Serena Mraz-Gernhard | Azithromycin for treatment of granulomatous rosacea |
| TWI435729B (zh) | 2005-11-09 | 2014-05-01 | Combinatorx Inc | 治療病症之方法，組合物及套組 |
| CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| EP2364707B1 (en) * | 2006-08-07 | 2013-04-03 | Bausch & Lomb Incorporated | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US20080286338A1 (en) | 2007-05-15 | 2008-11-20 | Boston Foundation For Sight | Drug delivery system with scleral lens |
| US8349806B2 (en) | 2008-07-10 | 2013-01-08 | Inspire Pharmaceuticals, Inc. | Method of treating blepharitis |
| US20100190734A1 (en) | 2009-01-23 | 2010-07-29 | Romulus Kimbro Brazzell | Method of treating dry eye disease with azithromycin |
-
2009
- 2009-07-10 US US12/501,316 patent/US8349806B2/en active Active
- 2009-07-10 MX MX2011000247A patent/MX2011000247A/es active IP Right Grant
- 2009-07-10 AU AU2009268372A patent/AU2009268372B2/en not_active Ceased
- 2009-07-10 WO PCT/US2009/050311 patent/WO2010006306A1/en not_active Ceased
- 2009-07-10 CA CA2730120A patent/CA2730120A1/en not_active Abandoned
- 2009-07-10 JP JP2011517670A patent/JP2011527709A/ja not_active Withdrawn
- 2009-07-10 EP EP09795262.6A patent/EP2313103B1/en not_active Not-in-force
-
2014
- 2014-09-18 JP JP2014190105A patent/JP2014240433A/ja not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001089378A (ja) * | 1999-08-09 | 2001-04-03 | Sifi Soc Industria Farmaceutica It Spa | 眼科用水性薬剤の製造方法 |
Non-Patent Citations (4)
| Title |
|---|
| JPN6013043214; ＡｚａＳｉｔｅ（Ｒ）添付文書 * |
| JPN6013043215; Ｊｏｕｒｎａｌ ｏｆ Ｏｐｈｔｈａｌｍｉｃ Ｎｕｒｓｉｎｇ ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ，１９９９，Ｖｏｌ．１８，Ｎｏ．３，ｐ．１０９-１１５ * |
| JPN6013043216; Ｃｌｉｎｉｃａｌ Ｏｐｈｔｈａｌｍｏｌｏｇｙ，２００７，Ｖｏｌ．１，ＮＯ．１，ｐ．３-１０ * |
| JPN6013043217; Ｔｈｅ Ａｎｎａｌｓ ｏｆ Ｐｈａｒｍａｃｏｔｈｅｒａｐｙ，２００５，Ｖｏｌ．３９，ｐ．８６-９４ * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014023526A (ja) * | 2012-06-19 | 2014-02-06 | Santen Pharmaceut Co Ltd | ヘアレス動物の眼瞼状態の変化方法 |
| JPWO2017110874A1 (ja) * | 2015-12-22 | 2018-11-15 | 日油株式会社 | 涙液油層安定化剤およびこれを含有する点眼剤 |
| WO2021261576A1 (ja) * | 2020-06-26 | 2021-12-30 | 参天製薬株式会社 | 脂質分泌促進剤 |
| JP2023550632A (ja) * | 2020-11-23 | 2023-12-04 | サイト サイエンシーズ， インコーポレイテッド | 眼の症状を処置するための製剤および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011000247A (es) | 2011-03-30 |
| CA2730120A1 (en) | 2010-01-14 |
| US8349806B2 (en) | 2013-01-08 |
| EP2313103A1 (en) | 2011-04-27 |
| AU2009268372B2 (en) | 2015-06-04 |
| JP2014240433A (ja) | 2014-12-25 |
| WO2010006306A1 (en) | 2010-01-14 |
| EP2313103A4 (en) | 2012-08-08 |
| EP2313103B1 (en) | 2014-06-18 |
| AU2009268372A1 (en) | 2010-01-14 |
| US20100022465A1 (en) | 2010-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014240433A (ja) | 眼瞼炎の治療方法 | |
| Luchs | Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis | |
| CN113056353B (zh) | 用于治疗干眼病的调配物 | |
| Friedlaender et al. | A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis | |
| Oltz et al. | Rosacea and its ocular manifestations | |
| JP2011515494A (ja) | テトラサイクリンファミリー抗生物質を用いる、眼瞼縁および涙液膜機能の改善ならびに眼瞼縁疾患の処置のための方法 | |
| Seal et al. | Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. | |
| TWI650122B (zh) | 用於預防及／或治療乾眼症之組成物、方法及／或裝置 | |
| Asbell et al. | A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis | |
| EP2393355A1 (en) | Method of treating dry eye disease with azithromycin | |
| US20130281390A1 (en) | Method for treating dry eye | |
| CZ200136A3 (cs) | Vitamín E a jeho estery pro použití při lokální léčbě onemocnění sliznice | |
| US20130274214A1 (en) | Method for treating blepharitis | |
| Lane | Nepafenac: a unique nonsteroidal prodrug | |
| CN114096244A (zh) | 治疗眼病 | |
| Fujishima et al. | Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis | |
| US20170239307A1 (en) | Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies | |
| US20250262331A1 (en) | Composition and methods for improving signs and symptoms of ocular disorders | |
| US20110245190A1 (en) | Method for improving post surgery visual acuity outcome with azithromycin | |
| AU2019230220B2 (en) | Methods of use and pharmaceutical compositions of a selective Syk inhibitor | |
| Skrypnyk et al. | Effective strategies for the treatment of eyelid diseases in modern ophthalmology | |
| EP4442269A1 (en) | Novel use of alanyl-glutamine and ophthalmic composition comprising alanyl-glutamine | |
| HK40090169A (zh) | 用於治疗干眼病的调配物 | |
| Theodosiadis et al. | Non-inferiority evaluation of preservative-free latanoprost/timolol eye drops solution versus preserved latanoprost/timolol eye drops in patients with high intraocular pressure and open-angle glaucoma | |
| Kupecz et al. | Keeping up with recent ophthalmic drug approvals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120522 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120522 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131202 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131209 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140918 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140925 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20141030 |